Cite
HARVARD Citation
He, S. et al. (2022). A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer. Drug delivery. pp. 1243-1256. [Online].